Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10351 - 10375 of 10678 in total
LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).
Investigational
Matched Iupac: … 2,2-dimethyl-3-(4-{2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin …
Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).
Investigational
Matched Iupac: … N-[6-(4-{5-[2-(pyridin-2-yl)acetamido]-1,3,4-thiadiazol-2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluoromethoxy …
Epalrestat is under investigation in clinical trial NCT03244358 (Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer).
Investigational
Matched Iupac: … 2-[(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic …
Experimental
Matched Iupac: … (1R,3R,5S)-8-[(4-butoxyphenyl)methyl]-3-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-8-methyl-8-azabicyclo …
Experimental
Matched Iupac: … N-(5-{[4-(2-hydroxyacetyl)piperazin-1-yl]methyl}-2-[(1E)-2-(1H-indazol-3-yl)ethenyl]phenyl)-3-methylthiophene …
Investigational
Matched Iupac: … 5-{[6-(1-cyclopropyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]difluoromethyl}-6-fluoro-2 …
Investigational
Matched Iupac: … N-{5-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-4,6-dioxo-4H,5H,6H-thieno[3,4-c]pyrrol …
Experimental
Matched Iupac: … (4S)-1-phenyl-7-(pyridin-3-yl)heptan-4-yl (2S)-1-[2,2-difluoro-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine …
Dirlotapide is a drug employed in the treatment of obesity in dogs. It is marketed by Pfizer and Zoetis under the brand name, Slentrol, and is not intended for human use.
Investigational
Vet approved
Matched Iupac: … N-[(S)-[benzyl(methyl)carbamoyl](phenyl)methyl]-1-methyl-5-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-amido …
Cinepazide has been used in trials studying the treatment of Ischemic Stroke.
Investigational
Matched Iupac: … (2E)-1-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl}-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one …
Tivantinib has been investigated in Solid Tumors.
Investigational
Matched Iupac: … (3R,4R)-3-{1-azatricyclo[6.3.1.0^{4,12}]dodeca-2,4,6,8(12)-tetraen-3-yl}-4-(1H-indol-3-yl)pyrrolidine …
GDC-0152 has been used in trials studying the treatment of Solid Cancers.
Investigational
Matched Iupac: … (2S)-1-[(2S)-2-cyclohexyl-2-[(2S)-2-(methylamino)propanamido]acetyl]-N-(4-phenyl-1,2,3-thiadiazol-5-yl …
Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).
Investigational
Matched Iupac: … 1-{3-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol …
Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).
Investigational
Matched Iupac: … N-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-5-({6-[(methylamino)methyl]pyrimidin-4-yl}oxy)-1H-indole …
GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).
Investigational
Matched Iupac: … 2-[(5-chloro-2-{[3-methyl-1-(propan-2-yl)-1H-pyrazol-5-yl]amino}pyridin-4-yl)amino]-N-methoxybenzamide …
Experimental
Matched Iupac: … 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine …
Experimental
Matched Iupac: … 3-{1-[3-(dimethylamino)propyl]-1H-indol-3-yl}-4-(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione …
Experimental
Matched Iupac: … lambda4-iron(4+) 2-[(E)-{[5-(2-carboxyethyl)-2-[(E)-[(2-oxidophenyl)methylidene]amino]phenyl]imino}methyl …
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Investigational
Matched Iupac: … 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}-1H-pyrazol-4-yl)-2,3,6,7-tetrahydro-1H-purine …
C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is...
Investigational
Matched Iupac: … }propanamido)-4-(trimethylazaniumyl)butanoate ... (3R)-3-(3-{[(1S)-1-{[(2S)-5-carbamimidamido-1,1-diethoxypentan-2-yl]carbamoyl}-3-methylbutyl]carbamoyl …
A P2Y12 inhibitor and platelet aggregation inhibitor.
Investigational
Matched Iupac: … 3-[(5-chlorothiophen-2-yl)sulfonyl]-1-{4-[6-fluoro-7-(methylamino)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin …
Investigational
Matched Iupac: … (3R)-3-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methyl]-4-hydroxybutyl (2S)-2-amino-3-methylbutanoate …
Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to...
Investigational
Matched Iupac: … 3-(2-methoxyethyl) 5-(2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5 …
Experimental
Vet approved
Matched Iupac: … 2-({4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylphenyl}formamido …
Fedovapagon has been used in trials studying the treatment of Nocturia.
Investigational
Matched Iupac: … (2S)-N2,N2-dimethyl-N1-{[2-methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl]methyl}pyrrolidine …
Displaying drugs 10351 - 10375 of 10678 in total